Tenvir-EM Tablet (Emtricitabine 200mg. + Tenofovir disoproxil fumarate 300mg.)

What is Tenvir-EM Tablet (Emtricitabine 200mg. + Tenofovir disoproxil fumarate 300mg.)?

Tenvir-EM Tablet is a fixed-dose combination antiretroviral medication containing Emtricitabine 200mg and Tenofovir disoproxil fumarate 300mg. It is prescribed for the treatment of HIV-1 infection in adults and adolescents. This medication works by inhibiting reverse transcriptase, an enzyme essential for HIV replication, thereby reducing viral load and improving immune function. While not a cure, Tenvir-EM helps manage HIV progression and may be used as part of pre-exposure prophylaxis (PrEP) in high-risk individuals. It must be taken exactly as prescribed and is often used alongside other antiretroviral drugs for optimal control.

Key features

• Dual Active Ingredients — Combines Emtricitabine and Tenofovir for enhanced antiviral effect.
• HIV Treatment — Reduces viral load and helps preserve CD4 cell count.
• PrEP Eligibility — Approved for pre-exposure prophylaxis in at-risk populations.
• Once-Daily Dosing — Convenient regimen improves adherence.
• Oral Tablet Form — Easy administration with or without food.
• Prescription Required — Must be used under medical supervision.
• Long-Term Management — Supports chronic HIV control when used consistently.

Who is Tenvir-EM Tablet (Emtricitabine 200mg. + Tenofovir disoproxil fumarate 300mg.) for?

This medication is intended for adults and adolescents weighing at least 35 kg who are living with HIV-1 or who are at high risk of contracting HIV and eligible for PrEP. It is not recommended for individuals with unknown HIV status, hepatitis B co-infection without monitoring, or severe kidney impairment. Patients must undergo testing before starting therapy and maintain regular follow-ups to monitor response and side effects.

How does Tenvir-EM Tablet (Emtricitabine 200mg. + Tenofovir disoproxil fumarate 300mg.) compare?

Compared to other antiretroviral regimens, Tenvir-EM offers a simplified, once-daily dosing option with proven efficacy in both treatment and prevention. It is bioequivalent to branded counterparts like Truvada but often available at lower cost. Unlike single-agent therapies, its dual mechanism reduces the risk of resistance. It is less potent than complete HAART regimens but serves as a critical backbone component. Among PrEP options, it is comparable to other FTC/TDF-based tablets but requires strict adherence for maximum protection.